

PCT and MR-proADM

Utility in improving patient management during COVID-19 and beyond

Web Symposium 17.09.2020 | 11.45 -12.30 CET

11.45 – 12.20

Clinical utility of procalcitonin in the management of COVID-19 patients

Michael K. Mansour, Massachusetts General Hospital, Boston, USA

Prognostic significance of admission MR-proADM levels in COVID-19 patients

Philipp Schuetz, Medizinische Universitätsklinik, Kantonsspital Aarau, Switzerland

Improving discharge in the ED: identifying patients with suspicion of infection in the ED who have low disease severity using MR-proADM

Juan Gonzalez del Castillo, Hospital Clinico San Carlos, Madrid, Spain

12.20 – 12.30

Live Q&A session

During this webinar, participants will:

- Gain an understanding of the utility of Procalcitonin in the early identification of COVID-19 patients at low risk of bacterial coinfection and adverse outcomes.
- Get to know new data on the prognostic significance of MR-proADM measured through hospital admissions of COVID-19 patients.
- Go beyond COVID-19 and be the first to learn about the results of the interventional trial IDEAL and how MR-proADM can improve discharge decisions.

Find out more at thermoscientific.com/procalcitonin